As Some VCs Run On Empty, Others Are Topping Off The Tank
This article was originally published in Start Up
Executive Summary
New money is increasingly hard to come by for life sciences venture capital firms. Start-Up tracks VCs to determine which firms have older vintage funds and which have plenty of fresh capital to invest.
You may also be interested in...
In 2012, Biotech IPOs Continue Their Inside Story
Among the new realities for life science VCs, from structured acquisitions to no-go therapeutic areas, it looks like we can add insider participation in IPOs to the list. It's been nearly a year since a life-science company went public in the US without its private investors pitching in.
START-UP's 2011 Life Science Venture Capital Survey: Device Investors Feel The Sting Of FDA, Economy And Reform
START-UP's first life science venture survey asked all VCs how they feel about the state of the industry. Medical device VCs' answers reveal feelings of being beaten down by the FDA and the recession, and general concerns about the sector's ability to generate returns. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."
START-UP's 2011 Life Science Venture Capital Survey: Biopharmaceutical Investors Let Some Sunshine In
In START-UP's first life science venture survey, biopharma investors have plenty to complain about -- and they do -- but their generally positive outlook stands in contrast to that of their peers focused on medtech. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."